Spire Therapeutics

San Diego, United States· Est. 2018

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Spire Therapeutics is pioneering a novel, non-invasive neuromodulation platform using transcranial focused ultrasound (tFUS) to treat severe neurological conditions. Its lead device, Diadem, is designed to overcome key technical barriers like skull and hair distortion to deliver precise, controlled therapy to deep brain targets. The company is currently conducting Phase 3 clinical trials for chronic pain and depression, supported by prestigious grants and private investment, positioning it to address a large unmet need in treatment-resistant patient populations.

Chronic PainDepressionNeurological Disorders

Technology Platform

Diadem: A non-invasive transcranial focused ultrasound (tFUS) device that compensates for skull and hair distortion to precisely neuromodulate deep brain circuits.

Opportunities

The primary opportunity is addressing the large unmet need in the ~26 million U.S.

patients with treatment-resistant chronic pain and depression.

Success could establish a new, non-invasive standard of care in neuromodulation.

The Diadem platform also has potential for expansion into other neurological and psychiatric disorders.

Risk Factors

Key risks include clinical trial failure in ongoing Phase 3 studies, regulatory hurdles for a novel Class III medical device, and challenges in achieving commercial adoption, physician training, and insurance reimbursement.

Competition from other neuromodulation technologies is also a factor.

Competitive Landscape

Spire competes in the neuromodulation market against established technologies like Transcranial Magnetic Stimulation (TMS) for depression and spinal cord stimulators for pain. Its key differentiation is non-invasive deep brain targeting, a capability primarily found only in invasive Deep Brain Stimulation (DBS). It faces competition from other companies developing next-generation non-invasive neuromodulation technologies.